Quarterly ResultMay 12, 2026, 04:23 PM
Lineage Cell Therapeutics Q1 Net Loss $(4.81M); Revenue $1.73M
AI Summary
Lineage Cell Therapeutics reported a net loss attributable to Lineage of $(4.81) million for the first quarter of 2026, an increase from $(4.14) million in the prior year. Total revenues increased to $1.73 million from $1.50 million, driven by higher collaboration revenues. The company ended the quarter with $53.4 million in cash, cash equivalents, and marketable securities, and believes this is sufficient to fund operations for at least the next twelve months.
Key Highlights
- Net loss attributable to Lineage was $(4.81) million, compared to $(4.14) million in Q1 2025.
- Total revenues increased to $1.73 million from $1.50 million in Q1 2025.
- Collaboration revenues rose to $1.58 million from $1.27 million year-over-year.
- Research and development expenses increased to $4.23 million from $3.11 million.
- General and administrative expenses were $5.08 million, up from $4.86 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $53.4 million as of March 31, 2026.
- Net cash used in operating activities was $(8.08) million, compared to $(4.89) million in Q1 2025.
Price Impact
More from LCTX